Skip to content

Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients

Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07643597
Acronym
VINKO
Enrollment
128
Registered
2026-06-11
Start date
2026-07-06
Completion date
2027-12-01
Last updated
2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Critical Illness, Fluid Overload, Fluid Overload in Dialysis Patients, Renal Replacement Therapy for Acute Kidney Injury in ICU

Keywords

Net Ultrafiltration, Continuous Renal Replacement Therapy, Fluid Removal, Ultrafiltration Intolerance, Tissue Hypoperfusion, Fluid Overload, VExUS, Point-of-Care Ultrasound

Brief summary

Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor tissue perfusion during this process. The purpose of this prospective observational study is to evaluate tolerance to net ultrafiltration in critically ill patients with AKI receiving CRRT. The study will assess clinical, hemodynamic, ultrasound, perfusion, and biochemical parameters before and during fluid removal to identify factors associated with ultrafiltration intolerance. The investigators hypothesize that alterations in hemodynamic, perfusion, and congestion-related parameters can identify patients at increased risk of ultrafiltration intolerance before the development of overt hypotension. The results may help improve individualized fluid removal strategies and optimize the safety of CRRT in critically ill patients.

Detailed description

Fluid overload is a frequent and clinically relevant complication in critically ill patients with acute kidney injury (AKI). In this setting, continuous renal replacement therapy (CRRT) is frequently used not only for solute control but also as a strategy for controlled fluid removal through net ultrafiltration (UFNET). Although UFNET is central to de-resuscitation, the individual tolerance to fluid removal is highly variable and is not fully captured by blood pressure monitoring alone. The concept of ultrafiltration intolerance remains poorly standardized. In clinical practice, intolerance is often recognized only after overt hemodynamic instability occurs, such as hypotension, escalation of vasoactive support, or interruption of fluid removal. However, reductions in cardiac output, impaired tissue perfusion, or worsening venous congestion may precede overt hypotension. Therefore, a multiparametric assessment may allow earlier identification of patients at risk. This is a prospective, observational, analytical study in critically ill adult patients with AKI receiving CRRT with prescribed UFNET. The study does not assign or modify therapeutic interventions. CRRT modality, anticoagulation strategy, UFNET prescription, vasopressor management, fluid administration, and all other clinical decisions will remain under the responsibility of the treating clinical team according to routine care. The study will characterize the physiological response to UFNET using a structured multiparametric monitoring approach. Recorded domains will include conventional macrohemodynamic variables, vasoactive support, selected advanced hemodynamic variables when available, focused cardiac ultrasound, venous congestion assessment, peripheral perfusion parameters, fluid balance variables, and selected biochemical markers. Functional hemodynamic maneuvers may be performed when feasible and clinically safe. Data will be collected prospectively using a standardized case report form. Variables will be recorded at predefined time points before and during the early phase of UFNET, with additional off-schedule recordings if clinical signs compatible with intolerance occur. Source data will be obtained from the electronic or paper medical record, bedside monitoring systems, CRRT prescription and treatment records, laboratory results, and ultrasound assessments performed as part of clinical evaluation. A data dictionary will define each variable, including its source, units, coding, and expected physiological range when applicable. Data quality procedures will include review of completeness, range checks, consistency checks between related variables, and verification of clinically implausible values against source records. The research team will periodically review entered data to identify missing, inconsistent, or out-of-range values. Data will be anonymized before analysis. No directly identifiable patient information will be stored in the final analytical database. Access to the study database will be restricted to authorized study investigators. Data will be stored using password-protected institutional or investigator-controlled systems according to local confidentiality and ethical requirements. The planned sample size is 128 participants, including an estimated analytical sample of 116 participants and an approximate 10% over-recruitment to account for incomplete data, missing assessments, or inability to definitively adjudicate the outcome. The sample size was based on an analytical case-control approach aimed at identifying factors associated with ultrafiltration intolerance. Missing data will be evaluated before statistical analysis. Variables with substantial missingness may be excluded from inferential analyses. For variables with acceptable levels of missingness, available-case analysis will be performed. The extent and pattern of missing data will be reported. Statistical analysis will include descriptive statistics, comparison between patients who develop ultrafiltration intolerance and those who do not, and exploratory modeling to identify factors independently associated with intolerance. Continuous variables will be summarized using median and interquartile range or mean and standard deviation, as appropriate. Categorical variables will be summarized as frequencies and percentages. Group comparisons will be performed using appropriate parametric or non-parametric tests according to data distribution. Multivariable logistic regression may be used to explore independent predictors, with covariate selection based on clinical relevance and number of events. The overall objective of this study is to improve the characterization of ultrafiltration intolerance during CRRT and to generate evidence that may support individualized, physiology-guided fluid removal strategies in critically ill patients with AKI.

Interventions

None listed

Sponsors

Hospital Las Higueras
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Admission to an Intensive Care Unit * Acute kidney injury according to KDIGO criteria * Prescription of continuous renal replacement therapy (CRRT) with net ultrafiltration * Clinical stability considered sufficient to initiate net ultrafiltration according to the treating clinical team

Exclusion criteria

* Chronic kidney replacement therapy prior to ICU admission * Pregnancy * Limitation of therapeutic effort or goals-of-care decisions at admission or during the observation period * Inability to perform hemodynamic or perfusion assessment * Extracorporeal membrane oxygenation (ECMO) * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Development of Ultrafiltration IntoleranceFrom UFNET initiation (T0) to 24 hours after initiation of net ultrafiltrationProportion of patients who develop ultrafiltration intolerance according to the protocol-defined composite criteria, including hypotension, increased vasopressor requirements, worsening peripheral perfusion, tissue hypoperfusion, or reduction/interruption of ultrafiltration due to instability.

Secondary

MeasureTime frameDescription
Incidence of Ultrafiltration IntoleranceFrom UFNET initiation (T0) to 24 hours.Percentage of participants who develop ultrafiltration intolerance during the observation period.
Net Ultrafiltration Rate (mL/kg/h)From UFNET initiation (T0) to 24 hours.Prescribed and achieved net ultrafiltration rate during continuous renal replacement therapy.
Time to First Ultrafiltration Intolerance Event (hours)From UFNET initiation to 24 hours.Time from UFNET initiation to the first occurrence of ultrafiltration intolerance.
Severity Category of Ultrafiltration IntoleranceFrom UFNET initiation to 24 hours.Proportion of participants classified as having mild, moderate, or severe ultrafiltration intolerance according to protocol-defined criteria. Higher categories indicate greater severity of intolerance.
Agreement Between Hypotension-Based and Hypoperfusion-Based Definitions of Ultrafiltration IntoleranceFrom UFNET initiation to 24 hours.Agreement between intolerance defined by hypotension criteria and intolerance defined by tissue hypoperfusion criteria, assessed using Cohen's kappa coefficient.
Cumulative Fluid Balance (mL)24 hours after UFNET initiationCumulative fluid balance achieved during the first 24 hours following UFNET initiation.
Achieved Net Ultrafiltration Volume (mL)24 hours after UFNET initiationTotal net ultrafiltration volume achieved during the observation period.
Proportion of Participants Achieving Renal RecoveryUp to 90 days after UFNET initiationPercentage of participants who recover kidney function sufficiently to discontinue kidney replacement therapy according to the treating clinical team.
Ventilator-Free DaysUp to 28 days after UFNET initiationNumber of days alive and free from invasive mechanical ventilation.
Intensive Care Unit MortalityFrom UFNET initiation up to 90 days or ICU discharge, whichever occurs firstPercentage of participants who die during intensive care unit admission.
Hospital MortalityFrom UFNET initiation until hospital discharge, assessed up to 180 daysPercentage of participants who die during hospital admission.

Countries

Brazil, Chile, Colombia, Ecuador, Italy, Mexico, Peru

Contacts

CONTACTGonzalo Ramírez-Guerrero, MD
ramirezguerrero.g@gmail.com+56981746173
CONTACTCristian Pedreros-Rosales, MD
cpedreros@me.com
PRINCIPAL_INVESTIGATORGonzalo Ramírez-Guerrero, MD

Hospital Las Higueras de Talcahuano

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026